Details for New Drug Application (NDA): 020584
✉ Email this page to a colleague
The generic ingredient in LODINE XL is etodolac. There are twenty-three drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the etodolac profile page.
Summary for 020584
Tradename: | LODINE XL |
Applicant: | Wyeth Pharms Inc |
Ingredient: | etodolac |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020584
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Oct 25, 1996 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 600MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Oct 25, 1996 | TE: | RLD: | Yes |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Jan 20, 1998 | TE: | RLD: | No |
Expired US Patents for NDA 020584
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Wyeth Pharms Inc | LODINE XL | etodolac | TABLET, EXTENDED RELEASE;ORAL | 020584-001 | Oct 25, 1996 | ⤷ Sign Up | ⤷ Sign Up |
Wyeth Pharms Inc | LODINE XL | etodolac | TABLET, EXTENDED RELEASE;ORAL | 020584-002 | Oct 25, 1996 | ⤷ Sign Up | ⤷ Sign Up |
Wyeth Pharms Inc | LODINE XL | etodolac | TABLET, EXTENDED RELEASE;ORAL | 020584-003 | Jan 20, 1998 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription